Single-Session Percutaneous Mechanical Thrombectomy Using the AspirexS Device Plus Stenting for Acute Iliofemoral Deep Vein Thrombosis: Safety, Efficacy, and Mid-Term Outcomes.

Fiche publication

Date publication

juillet 2020

Journal

Diagnostics (Basel, Switzerland)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr LOFFROY Romaric

Tous les auteurs :
Loffroy R, Falvo N, Guillen K, Galland C, Baudot X, Demaistre E, Fréchier L, Ledan F, Midulla M, Chevallier O

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32751767

Résumé

To assess the safety, efficacy and mid-term outcomes of single-session percutaneous mechanical thrombectomy (PMT) for acute symptomatic iliofemoral deep vein thrombosis (DVT) using the AspirexS device. Retrospective review of 30 patients (women, 23; mean age, 45.5 ± 19.9 years; range, 17-76) who underwent PMT with the 10-French AspirexS device (Straub Medical AG, Wangs, Switzerland) for acute DVT between December 2015 and March 2019. Procedures were performed by popliteal ( = 22) or jugular ( = 7) approach, or both ( = 1). Mean time from diagnosis to PMT was 5.5 ± 4.6 days (range, 2-11). Successful thrombus removal and venous patency restoration were achieved in all patients (100%). Fluid removal was 307.8 ± 66.1 mL (range, 190-410). Additional venous stenting rate was 100%. Mean procedural time was 107.3 ± 33.9 min (range, 70-180). No major complication occurred. The patient's postprocedural course was uneventful in all cases, with hospital discharge within 2 days in 83.3%. Early in-stent rethrombosis occurred within 1 week in 3 patients, successfully managed by endovascular approach. Secondary stent patency rate was 86.7% at a mean follow-up of 22.3 ± 14.2 months (range, 6-48), as assessed by Duplex ultrasound. Single-session of PMT using the AspirexS device is a safe and effective therapeutic option in patients presenting with acute symptomatic iliofemoral DVT.